Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

76.34USD
3:44pm BST
Change (% chg)

$0.24 (+0.32%)
Prev Close
$76.10
Open
$75.96
Day's High
$76.38
Day's Low
$75.67
Volume
214,342
Avg. Vol
1,848,746
52-wk High
$80.67
52-wk Low
$56.81

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $133,667.41
Shares Outstanding(Mil.): 1,756.47
Dividend: 0.32
Yield (%): 1.68

Financials

  ABT.N Industry Sector
P/E (TTM): 51.22 34.07 63.23
EPS (TTM): 1.49 -- --
ROI: -- 12.63 11.76
ROE: -- 14.88 12.60

Abbott Labs quarterly beat overshadowed by unchanged forecast

Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

17 Apr 2019

UPDATE 2-Abbott Labs quarterly beat overshadowed by unchanged forecast

April 17 Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

17 Apr 2019

Abbott Lab's first-quarter sales beat expectations

April 17 Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

17 Apr 2019

Abbott misses revenue estimates, sees lackluster first-quarter profit

Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

23 Jan 2019

UPDATE 3-Abbott misses revenue estimates, sees lackluster first-qtr profit

Jan 23 Abbott Laboratories missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

23 Jan 2019

Abbott Labs says M&A not a high priority now

Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

23 Jan 2019

Abbott Labs says M&A not a high priority now

Jan 23 Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

23 Jan 2019

Abbott Lab's fourth-quarter revenue rises 2.3 pct

Jan 23 Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.

23 Jan 2019

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

26 Oct 2018

UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

26 Oct 2018

Earnings vs. Estimates